Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$104.40 -0.5%	$102.02	$76.53 ▼ $131.49	$25.10B	1.29	949,716 shs	894,938 shs
ONC BeOne Medicines	$252.78 -0.5%	$245.25	$141.31 ▼ $287.88	$27.69B	0.3	309,136 shs	230,441 shs
SMMT Summit Therapeutics	$20.16 +1.6%	$23.81	$6.78 ▼ $36.91	$14.97B	-1.06	3.64 million shs	2.83 million shs
TGTX TG Therapeutics	$35.17 +0.5%	$37.20	$16.65 ▼ $46.48	$5.58B	1.94	2.96 million shs	1.77 million shs

20 Stocks to Sell Now

Today, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.

Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-0.50%	+2.63%	+9.46%	+21.02%
ONC BeOne Medicines	0.00%	-8.59%	+6.72%	+0.32%	+25,277,999,900.00%
SMMT Summit Therapeutics	0.00%	0.00%	-17.34%	+2.08%	+153.90%
TGTX TG Therapeutics	0.00%	-5.89%	-0.85%	-18.19%	+109.72%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BNTX BioNTech	2.8895 of 5 stars	4.4	3.0	0.0	2.3	0.8	0.0
ONC BeOne Medicines	2.5563 of 5 stars	3.5	0.0	0.0	3.0	1.7	0.6
SMMT Summit Therapeutics	3.1313 of 5 stars	4.4	3.0	0.0	2.6	1.7	0.0
TGTX TG Therapeutics	3.5347 of 5 stars	2.4	1.0	3.5	1.4	2.5	1.9

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.83	Moderate Buy	$137.86	32.05% Upside
ONC BeOne Medicines	3.00	Buy	$319.00	26.20% Upside
SMMT Summit Therapeutics	2.77	Moderate Buy	$35.09	74.06% Upside
TGTX TG Therapeutics	2.80	Moderate Buy	$40.80	16.01% Upside

Current Analyst Ratings Breakdown

Latest TGTX, BNTX, ONC, and SMMT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/16/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$145.00 ➝ $138.00
6/11/2025	SMMT Summit Therapeutics	Leerink Partnrs Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong Sell
6/11/2025	SMMT Summit Therapeutics	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Underperform	$12.00
6/5/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$134.00 ➝ $145.00
6/3/2025	BNTX BioNTech	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$151.00 ➝ $155.00
6/2/2025	BNTX BioNTech	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target		$112.00
6/2/2025	SMMT Summit Therapeutics	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$40.00
5/29/2025	BNTX BioNTech	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy ➝ Neutral	$110.00
5/22/2025	BNTX BioNTech	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$120.00 ➝ $116.00
5/22/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$134.00 ➝ $134.00
5/14/2025	BNTX BioNTech	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$145.00 ➝ $134.00

(Data available from 6/20/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$2.98B	8.43	N/A	N/A	$87.61 per share	1.19
ONC BeOne Medicines	$3.81B	7.27	N/A	N/A	$34.10 per share	7.41
SMMT Summit Therapeutics	$700K	21,388.90	N/A	N/A	$0.53 per share	38.04
TGTX TG Therapeutics	$329M	16.97	$0.12 per share	293.13	$1.43 per share	24.59

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$719.92M	-$3.40	N/A	N/A	N/A	-27.37%	-3.94%	-3.41%	8/4/2025 (Estimated)
ONC BeOne Medicines	-$644.79M	-$3.72	N/A	356.03	N/A	-9.40%	-7.55%	-4.42%	N/A
SMMT Summit Therapeutics	-$221.32M	-$0.34	N/A	N/A	N/A	N/A	-62.87%	-51.61%	8/5/2025 (Estimated)
TGTX TG Therapeutics	$23.38M	$0.24	146.54	35.17	N/A	10.13%	18.88%	7.05%	8/5/2025 (Estimated)

Latest TGTX, BNTX, ONC, and SMMT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/7/2025	Q1 2025	ONC BeOne Medicines	-$0.71	$1.22	+$1.93	$0.01	$1.12 billion	$1.12 billion
5/7/2025	Q1 2025	TGTX TG Therapeutics	$0.19	$0.03	-$0.16	$0.03	$117.07 million	$120.86 million
5/1/2025	Q1 2025	SMMT Summit Therapeutics	-$0.10	-$0.09	+$0.01	-$0.09	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
ONC BeOne Medicines	N/A	N/A	N/A	N/A	N/A
SMMT Summit Therapeutics	N/A	N/A	N/A	N/A	N/A
TGTX TG Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	10.18	10.02
ONC BeOne Medicines	0.05	1.96	1.71
SMMT Summit Therapeutics	N/A	10.63	10.63
TGTX TG Therapeutics	1.03	4.02	3.04

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
ONC BeOne Medicines	48.55%
SMMT Summit Therapeutics	4.61%
TGTX TG Therapeutics	58.58%

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
ONC BeOne Medicines	6.62%
SMMT Summit Therapeutics	84.90%
TGTX TG Therapeutics	10.64%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	6,772	240.39 million	194.24 million	Optionable
ONC BeOne Medicines	11,000	109.56 million	102.31 million	N/A
SMMT Summit Therapeutics	110	742.67 million	112.14 million	Optionable
TGTX TG Therapeutics	290	158.76 million	141.86 million	Optionable

TGTX, BNTX, ONC, and SMMT Headlines

Recent News About These Companies

Insider Selling: Yann Echelard Unloads $369K Of TG Therapeutics Stock

June 17 at 6:31 PM | benzinga.com

Are Options Traders Betting on a Big Move in TG Therapeutics Stock?

June 17 at 11:40 AM | msn.com

Yann Echelard Sells 10,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX) Stock

June 17 at 4:32 AM | insidertrades.com

Insider Selling: TG Therapeutics, Inc. (NASDAQ:TGTX) Director Sells 10,000 Shares of Stock

June 16, 2025 | marketbeat.com

Cantor Fitzgerald Predicts TG Therapeutics FY2026 Earnings

June 11, 2025 | americanbankingnews.com

Cantor Fitzgerald Estimates TG Therapeutics FY2026 Earnings

June 10, 2025 | marketbeat.com

GAMMA Investing LLC Purchases 176,573 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 9, 2025 | marketbeat.com

TG Therapeutics (NasdaqCM:TGTX) Stock Rises 13% In Last Month

June 7, 2025 | uk.finance.yahoo.com

TG Therapeutics to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference

June 6, 2025 | globenewswire.com

Wellington Management Group LLP Trims Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

Two Sigma Advisers LP Sells 214,800 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

June 6, 2025 | marketbeat.com

TG Therapeutics (NASDAQ:TGTX) Trading Up 6.2% - Still a Buy?

June 5, 2025 | marketbeat.com

Mackenzie Financial Corp Cuts Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 5, 2025 | marketbeat.com

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Reduces Stock Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

June 1, 2025 | marketbeat.com

NorthCrest Asset Manangement LLC Invests $448,000 in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 31, 2025 | marketbeat.com

TG Therapeutics Announces Data Presentations for BRIUMVI in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 30, 2025 | theglobeandmail.com

Man Group plc Purchases Shares of 9,589 TG Therapeutics, Inc. (NASDAQ:TGTX)

May 29, 2025 | marketbeat.com

TG Therapeutics: Estimates Could Soon Be Raised Again

May 28, 2025 | seekingalpha.com

Bank of America Corp DE Has $6.95 Million Stake in TG Therapeutics, Inc. (NASDAQ:TGTX)

May 28, 2025 | marketbeat.com

TG Therapeutics Announces Schedule of Data Presentations for BRIUMVI® in Multiple Sclerosis at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting

May 27, 2025 | globenewswire.com

Connecticut Wealth Management LLC Sells 13,000 Shares of TG Therapeutics, Inc. (NASDAQ:TGTX)

May 25, 2025 | marketbeat.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
By Leo Miller | May 27, 2025
View 3 Beaten-Down Stocks Trading 50% Below Their 52-Week Highs
Turbulence for Joby Shares: What's Behind the Recent Dip?
By Jeffrey Neal Johnson | May 22, 2025
View Turbulence for Joby Shares: What's Behind the Recent Dip?
RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
By Ryan Hasson | June 11, 2025
View RKLB Breakout Fails Near Highs: Should Investors Be Concerned?
Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
By Leo Miller | June 2, 2025
View Analysts Are Bullish on Marvell Stock Despite Amazon Deal Concern
Palantir Soars on Government Deals as Valuation Debate Lingers
By Chris Markoch | June 3, 2025
View Palantir Soars on Government Deals as Valuation Debate Lingers

TGTX, BNTX, ONC, and SMMT Company Descriptions

BioNTech NASDAQ:BNTX

$104.40 -0.57 (-0.54%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$104.88 +0.48 (+0.46%)

As of 06/18/2025 07:20 PM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

BeOne Medicines NASDAQ:ONC

$252.78 -1.31 (-0.52%)

As of 06/18/2025 04:00 PM Eastern

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations. The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Basel, Switzerland.

Summit Therapeutics NASDAQ:SMMT

$20.16 +0.31 (+1.56%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$20.08 -0.08 (-0.39%)

As of 06/18/2025 07:55 PM Eastern

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies in the United States, and the United Kingdom. The company's lead development candidate is Ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis; and anti-infectives portfolio includes SMT-738, a novel class of precision antibiotics for the treatment of multidrug resistant infections, which primarily includes carbapenem-resistant Enterobacteriaceae infections. It has a collaboration and license agreement with Akeso, Inc. and its affiliates to develop and commercialize ivonescimab, as well as strategic collaboration with The University of Texas MD Anderson Cancer Center for the purpose of accelerating the development of ivonescimab. The company was founded in 2003 and is headquartered in Miami, Florida.

TG Therapeutics NASDAQ:TGTX

$35.17 +0.17 (+0.49%)

Closing price 06/18/2025 04:00 PM Eastern

Extended Trading

$35.38 +0.20 (+0.58%)

As of 06/18/2025 08:00 PM Eastern

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults. The company's development pipeline comprises Umbralisib, an oral inhibitor of PI3K-delta inhibitor for the treatment of adult patients with relapsed or refractory marginal zone lymphoma and follicular lymphoma; TG-1701 is an orally available and covalently bound Bruton's tyrosine kinase (BTK) inhibitor that exhibits selectivity to BTK in vitro kinase screening; and TG-1801, a bispecific CD47 and CD19 antibody. Its research pipeline includes various investigational medicines. The company has license agreements with LFB Biotechnologies S.A.S; GTC Biotherapeutics; LFB/GTC LLC; Ildong Pharmaceutical Co. Ltd.; Rhizen Pharmaceuticals, S A. for the development and commercialization of umbralisib; Jiangsu Hengrui Medicine Co.; and Novimmune SA, as well as collaboration agreement with Checkpoint Therapeutics, Inc. for the development and commercialization of anti-PD-L1 and anti-GITR antibody research programs in the field of hematological malignancies. TG Therapeutics, Inc. was incorporated in 1993 and is based in Morrisville, North Carolina.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time